Medulloblastoma molecular dissection: The way toward targeted therapy

Current Opinion in Oncology

Volumn 25, Issue 6, 2013, Pages 674-681

  Remke, Marc ^a,b   Ramaswamy, Vijay ^a,b   Taylor, Michael D ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

epigenetics; genomics; medulloblastoma; subgroup

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETA CATENIN; CD133 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; HISTONE H3; ITRACONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NUTLIN 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; ROMIDEPSIN; SMAD2 PROTEIN; SMAD4 PROTEIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR OTX2; TRANSFORMING GROWTH FACTOR BETA1; VALPROIC ACID; VISMODEGIB; VORINOSTAT; WNT PROTEIN;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CRANIOSPINAL IRRADIATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; IMMUNOREACTIVITY; MEDULLOBLASTOMA; NEURAL STEM CELL; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOBLASTOMA; REVIEW; SOMATIC MUTATION; UPREGULATION;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EPIGENOMICS; FEMALE; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; MALE; MEDULLOBLASTOMA; MOLECULAR TARGETED THERAPY; MUTATION; PROGNOSIS; QUALITY OF LIFE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 84885426091     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000008     Document Type: Review

References (51)

1. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 2011; 204:577-588.
2. Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29:1408-1414.
3. Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100-105.
4. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12:818-834.
5. Remke M, Hielscher T, Korshunov A, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011; 29:3852-3861.
6. Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 2011; 29:2717-2723.
7. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012; 123:465-472.
8. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblas-toma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012; 123:473-484.
9. Cho Y-J, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011; 29:1424-1430.
10. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 2006; 24:1924-1931.
11. Northcott PA, Shih DJ, Remke M, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuro-pathol 2012; 123:615-626.
12. Hovestadt V, Remke M, Kool M, et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 2013; 125:913-916.
13. Schwalbe EC, Williamson D, Lindsey JC, et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013; 125:359-371.
14. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011; 29:1400-1407.
15. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 2011; 121:381-396.
16. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24:4202-4208.
17. Jakacki RI, Burger PC, Zhou T, et al. Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study. J Clin Oncol 2012; 30:2648-2653.
18. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): longterm results from a prospective, multicentre trial. Lancet Oncol 2006; 7:813-820.
19. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medullo-blastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352:978-986.
20. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005; 23:7621-7631.
21. Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 2005; 23:5511-5519.
22. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006; 5:2666-2670.
23. Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005; 23:7951-7957.
24. Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 2012; 488:106-110.
25. Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 2013; 31:2927-2935.
26. Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol 2010; 6:829-836.
27. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 2010; 468:1095-1099.
28. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-851.
29. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medullo-blastoma. Nat Genet 2002; 31:306-310.
30. Wu X, Northcott PA, Croul S, et al. Mouse models of medulloblastoma. Chin J Cancer 2011; 30:442-449.
31. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109-1113.
32. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.
33. Dijkgraaf GJ, Alicke B, Weinmann L, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011; 71:435-444.
34. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-574.
35. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013; 23:23-34.
36. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblas-toma. Sci Transl Med 2010; 2:51ra70.
37. Secchiero P, Bosco R, Celeghini C, et al. Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011; 17:569-577.
38. Dubuc AM, Remke M, Korshunov A, et al. Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblas-toma. Acta Neuropathol 2013; 125:373-384.
39. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1000 medulloblastoma genomes. Nature 2012; 488:49-56.
40. Lin CP, Liu CR, Lee CN, et al. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010; 2:16-20.
41. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146:904-917.
42. Northcott PA, Nakahara Y, Wu X, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 2009; 41:465-472.
43. Pei Y, Moore CE, Wang J, et al. An animal model of MYC-driven medullo-blastoma. Cancer Cell 2012; 21:155-167.
44. Kawauchi D, Robinson G, Uziel T, et al. Amouse modelofthe most aggressive & subgroup of human medulloblastoma. Cancer Cell 2012; 21:168-180.
45. Swartling FJ, Savov V, Persson AI, et al. Distinct neural stem cell populations & give rise to disparate brain tumors in response to N-MYC. Cancer Cell 2012; 21:601-613.
46. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013; 3:308-323.
47. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science 2011; 331:435-439.
48. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012; 488:1-6.
49. Lee MG, Wynder C, Cooch N, et al. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005; 437:432-435.
50. Bunt J, Hasselt NA, Zwijnenburg DA, et al. OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels. Acta Neuropathol 2013; 125:385-394.
51. Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic diver-gence of metastatic medulloblastoma. Nature 2012; 482:529-533.